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Abstract
Background: Hashimoto’s thyroiditis is an autoimmune disorder and the most common cause of hypothyroidism.
The use of Nigella sativa, a potent herbal medicine, continues to increase worldwide as an alternative treatment of
several chronic diseases including hyperlipidemia, hypertension and type 2 diabetes mellitus (T2DM). The aim of the
current study was to evaluate the effects of Nigella sativa on thyroid function, serum Vascular Endothelial Growth
Factor (VEGF) – 1, Nesfatin-1 and anthropometric features in patients with Hashimoto’s thyroiditis.
Methods: Forty patients with Hashimoto’s thyroiditis, aged between 22 and 50 years old, participated in the trial
and were randomly allocated into two groups of intervention and control receiving powdered Nigella sativa or
placebo daily for 8 weeks. Changes in anthropometric variables, dietary intakes, thyroid status, serum VEGF and
Nesfatin-1 concentrations after 8 weeks were measured.
Results: Treatment with Nigella sativa significantly reduced body weight and body mass index (BMI). Serum
concentrations of thyroid stimulating hormone (TSH) and anti-thyroid peroxidase (anti-TPO) antibodies decreased
while serum T3 concentrations increased in Nigella sativa-treated group after 8 weeks. There was a significant
reduction in serum VEGF concentrations in intervention group. None of these changes had been observed in
placebo treated group. In stepwise multiple regression model, changes in waist to hip ratio (WHR) and thyroid
hormones were significant predictors of changes in serum VEGF and Nesgfatin-1 values in Nigella sativa treated
group (P < 0.05).
Conclusions: Our data showed a potent beneficial effect of powdered Nigella sativa in improving thyroid status
and anthropometric variables in patients with Hashimoto’s thyroiditis. Moreover, Nigella sativa significantly reduced
serum VEGF concentrations in these patients. Considering observed health- promoting effect of this medicinal plant
in ameliorating the disease severity, it can be regarded as a useful therapeutic approach in management of
Hashimoto’s thyroiditis.
Trial registration: Iranian registry of clinical trials (registration number IRCT2015021719082N4- Registered
March-15-2015).
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Background
Hashimoto’s thyroiditis (HT) is an organ-specific T-cell
mediated disease that affects the thyroid glands and is
one of the most common human autoimmune disorders
[1]. The disease affects 2% of general population and is
ten times more prevalent in women than in men [2, 3].
A significant proportion of patients have asymptomatic
chronic autoimmune thyroiditis and 8% of woman (10%
of woman over 55 years of age) and 3% of men have
subclinical hypothyroidism [4].
Hashimoto’s thyroiditis is characterized by the presence
of thyroid auto-antibodies such as anti-thyroid peroxidase
(TPO-Ab) and anti-thyroglobulin (TG-Ab) antibodies in
the serum while these antibodies have potential ability to
deteriorate thyroid cells [5, 6]. The disease is characterized
by gradual thyroid failure and occasional goiter develop-
ment and the untreated forms of Hashimoto’s thyroiditis
can ever lead to papillary thyroid cancer and thyroid
carcinoma [7, 8].
From pathological point of view, thyroid enlargement
and hyper-function in Hashimoto’s thyroiditis is accom-
panied by a markedly increased blood flow and increased
vascularization [9]. A number of growth and vasoactive
factors are produced in thyroid and are considered to be
potentially responsible for changes in thyroid microvas-
culature and blood flow; vascular endothelial growth fac-
tors (VEGF) is a hemodynamic glycoprotein with potent
angiogenic and vascular permeability enhancing activ-
ities [10]. It has been proposed that VEGF and its recep-
tors are present in epithelial cells of the thyroid and
contribute in regulation of development and function of
thyroid epithelial cells [10]. In fact VEGF is unique among
angiogenic factors because it is both vascular endothelial
cell-specific mitogen and is secreted by thyroid cancer
cells and high thyroid stimulating hormone (TSH) con-
centrations in Hashimoto’s thyroiditis promotes VEGF
secretion from thyroid cancer cell lines [11].
Nesfatin-1, a peptide secreting from peripheral tissues,
central and peripheral nervous system, is involved in the
regulation of energy homeostasis related with food con-
sumption mostly by passing through the blood–brain bar-
rier [12]. Moreover, several recent studies have proposed
the possible role of Nesfatin-1 in in thyroid dysfunction
[13, 14]. Liu et al. [15] reported that plasma Nesfain-1
levels are independently correlated with serum TSH con-
centrations in patients with T2DM. The Nesfatin-1
immuno-positive neurons have been reported to be co-
localized with thyrotropin releasing hormone (TRH)
neurons in the paraventricular nucleous (PVN) and the
central Nesfatin-1 affects the membrane potential of TRH
neurons suggesting the possible role of Nesfatin-1 in regu-
lation of thyroid hormone function [16, 17].
Levothyroxine sodium is the treatment of choice for
Hashimoto’s thyroiditis; however its chronic use is related
with cardiac dysfunction, left ventricular hypertrophy
[18, 19] and rapid bone loss [20]. Nigella sativa is one of
the medicinal plants and belongs to the Ranunculaceae
family [21]. The seeds of the Nigella sativa are the main
source of its active ingredients with considerable health
promoting effects including antioxidant, anti-inflammatory
and immune-modulatory properties and no side effects
[21, 22]. Numerous researches have extensively studied
therapeutic actions of Nigella sativa in improving chronic
disease status including diabetes, hyperlipidemia, hyperten-
sion and gastritis especially in animal models; while human
studies in this filed are scarce and limiting [23, 24]. More-
over the health effects of Nigella sativa in Hashimoto’s
thyroiditis has been studied in only one animal model indi-
cating its protective role in reversing hypothyroid status
and ameliorating oxidative stress and thyroid cell dam-
age in propylthiouracil (PTU)-induced hypothyroidism
in rats [25]. In the current randomized clinical trial we
aimed to evaluate the potential therapeutic effects of
Nigella sativa powder on thyroid function and serum




In the current double-blinded placebo-controlled trial,
40 patients with Hashimoto’s thyroiditis were enrolled
(Fig. 1). Subjects were recruited from outpatient endo-
crinology and metabolism clinics of Isfahan University of
Medical Sciences. Inclusion criteria were as follows: age
between 20 and 50 years and having Hashimoto’s thy-
roiditis according to physician diagnosis. Exclusion cri-
teria were as follows: taking any nutritional supplements
for at least 3 months prior participation or during the
trial, any history of autoimmune disease, cardiovascular
events, other thyroid abnormalities including Grave’s
disease, being pregnant or lactating, any history of thyroid
surgeries and being on any dietary regimens during and 3
months before recruitment in the trial. Participants were
treated with levothyroxine while the drug dosage was
stable from 6 weeks prior participation in the study to the
end of the trial. The average full replacement dose of
levothyroxine sodium was approximately 1.7 mcg/kg/day
(e.g., 100–125 mcg/day for a 70 kg adult).
Study design
From 100 recruited subjects, 53 participants were ex-
cluded because of not meeting the inclusion criteria or
decline to participate. Among remaining 47 patients,
random permuted block procedure was performed and
participants were randomly allocated into Nigella sativa-
treated (n = 23) or placebo-treated (n = 24) groups. Dur-
ing the trial, three patients in Nigella sativa-treated
group were excluded from the study because of itching
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and nausea; while four patients in control group refused
to continue the trial. Therefore, totally 20 patients in
each group completed the study. Patients in the inter-
vention group received a daily dose of 2 g Nigella sativa
powder per day and placebo group received 2 g starches
per day for 8 weeks. The dose of the Nigella sativa and
time period of the study had been selected according to
review of the previous studies indicating the effective-
ness of 2 g of Nigella sativa or even lesser doses and
8 weeks study duration in treatment of numerous meta-
bolic disorders including immune disturbances and lipid
abnormalities [26, 27].
Black seed powders were obtained from corns grown
in Isfahan bought by a local market (Sad-Giah market,
Isfahan, Iran) and were prepared by the Goldaroo
pharmaceutical company (Goldaro Pharmaceutical Co.
Isfahan, Iran). The black seeds were milled in a grinder
and a purified powder was prepared. The seeds were
identified and authenticated by Dr. Mahdieh Abbasalizad
Farhangi, supervisor of the project from Department of
Nutrition, Tabriz University of Medical Sciences, Tabriz,
Iran. Thereafter, Nigella sativa seeds were processed into
pharmaceutical grade capsules containing Nigella sativa
powder and bottled according to Good Manufacturing
Practices (GMP). Each capsule was prepared containing
1 g powder of Nigella Sativa, and each bottle contained
112 capsules, for 8 weeks period of the study. While for
the placebo, we used starch bought from the same
market and the entire processes of its capsulation was
similar to Nigella sativa seeds preparation. Partici-
pants in intervention and placebo groups received
two capsules daily, taking it immediately before lunch
and dinner respectively.
Randomization procedure was performed by a third
investigator who had no clinical involvement in the trial
to ensure complete blinding in the randomization process.
Randomization was done according to computer- gener-
ated numbers and was kept in consecutively numbered
envelopes opened at the moment of participant enroll-
ment into the study. A follow-up procedure was done with
weekly telephone contacts to ensure that subjects con-
sumed the supplements regularly.
Anthropometric and nutritional assessments
Body weight and height were measured with a calibrated
digital scale and stadimeter respectively. BMI was calcu-
lated as weight (kg) divided by height (cm) squared. Waist
circumference (WC) was measured in horizontal plane,
midway between the lowest rib and the iliac crest with a
measuring tape in centimeter. Waist to hip ratio (WHR)
was calculated by WC divided by hip circumference (HC).
The dietary assessments were performed using a 3-day
food record, covering two weekdays and one weekend
day, to estimate total energy, carbohydrate, protein, fat
and antioxidant vitamins consumption. Because of the
antioxidant nature of Nigella sativa the intake of vitamin E
and C were specifically evaluated to ensure that no change
in their consumption has been occurred throughout the
trial and to rule out their possible confounding effect on
study parameters. Nutrient analysis of the 3-day food
record was performed using the Nutritionist IV software
(N-squared Computing, Salem, OR, USA).
Fig. 1 CONSORT Flow diagram of subject recruitment
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Biochemical assays
Fasting blood samples were obtained from all of the
participants at the beginning and end of the trial. The
serum and plasma samples were separated by centrifuga-
tion at 2500 rpm for 10 min (Beckman Avanti J-25;
Beckman Coulter, Brea, CA, USA) at room temperature.
The serum samples were stored at −70 °C immediately
after centrifugation until their assays. Serum thyroid-
stimulating hormone (TSH), total triiodothyronine (T3)
and total thyroxine (T4) were analyzed by enzyme linked
immunosorbent assay (ELISA Kit, Pishtaz Tebe Co.,
Tehran, Iran) according to the manufacturer’s instruc-
tions. Anti-thyroid peroxidase antibody was measured
by the commercially solid-phase ELISA kit (Aeskulisa,
Wendelsheim, Germany). Serum concentration of VEGF
and Nesfatin-1 were measured by commercial ELISA kits
(Hangzhou East biopharm Co, USA). The sensitivity of
these assays was 10.42 ng/l and 0.15 ng/ml respectively.
Statistical assays
Statistical analysis was performed by SPSS™ statistical
software (SPSS Inc., Chicago, IL, USA). Quantitative data
were presented as mean ± standard deviation (SD), and
qualitative data were demonstrated as frequency and
percent. One-sample Kolmogorov-Smirnov test was
used to assess the normality of data. Between groups
comparisons of continuous variables were performed by
independent sample t-test. Paired t-test was used for before
and after intervention comparisons. Analysis of covariance
(ANCOVA) was used to identify any differences between
two treatment groups after intervention adjusting for the
confounding effects of baseline concentrations of para-
meter, age and gender. Stepwise multivariate linear regres-
sion model was used to evaluate the predictors of changes
in VEGF and Nesfatin-1 concentrations. P-values less than
0.05 were considered to be significant. Sample size calcula-
tion was performed based on 80% power and an α-error of
5% to detect treatment effect of Nigella sativa on serum
TSH. Totally, 14 individuals were calculated. Allowing for
30% drop-out over 8 weeks of intervention, the total sample
size required for the study was 40 individuals.
Results
The flowchart of the study is given in Fig. 1. A total of
40 patients completed the study. Three patients in
Nigella sativa-treated group were excluded from the
study because of itching and nausea; while four patients
in control group refused to continue the trial. No other
side effects were observed in the current study.
At baseline, there was no significant difference in
general characteristics among groups. Nigella sativa
supplementation significantly reduced anthropometric
variables including weight, BMI, WC and HC in patients
with Hashimoto’s thyroiditis (P < 0.05); while no significant
change in placebo-treated group has been occurred
(Table 1). Dietary energy and nutrient intakes before and
after intervention are presented in Table 2. Energy and
nutrient intakes were similar between groups before inter-
vention and no significant change was observed after inter-
vention. Serum TSH and anti-TPO concentrations reduced
while serum T3 increased in Nigella sativa treated group
(P < 0.05). Moreover, serum VEGF reduced significantly
after 8 weeks of Nigella sativa supplementation (P = 0.02,
Table 3). In stepwise multiple linear regression analysis
when change in serum VEGF concentrations was entered
as dependent variable and change in anthropometric vari-
ables and thyroid hormones as independent variables
(Table 4) one model was obtained indicating change in
WHR as predictor of change in VEGF concentrations. In
similar procedure when change in serum Nesfatin-1 was
entered as dependent variable, change in WHR, TSH and
T3 were its predictors (P < 0.05).
Table 1 General characteristics and anthropometric variables in
treatment groups before and after intervention
N Nigella sativa Placebo P†
N = 20 N = 20
Age (years) 35.70 ± 8.18 33.95 ± 8.72 0.52
Levothyroxine (mcg/d) 119.85 ± 24.12 118.46 ± 22.12 0.91
Female [n (%)] 17 (85) 17 (85) 0.89
Weight (kg)
Before 70.52 ± 12.27 69.63 ± 11.75 0.81
After 69.39 11.84 69.62 11.80 0.95
P‡ 0.004 0.91
BMI (kg/m2)
Before 27.10 ± 4.63 25.93 ± 4.07 0.40
After 26.63 4.42 25.95 4.11 0.61
P‡ 0.002 0.65
Waist Circumference (cm)
Before 88.56 ± 7.29 88.69 ± 7.41 0.95
After 87.72 ± 6.92 88.57 ± 7.35 0.71
P‡ 0.006 0.17
HC (cm)
Before 102.85 ± 6.25 101.77 ± 6.84 0.61
After 101.56 ± 5.51 101.56 ± 7.02 0.99
P‡ 0.001 0.08
WHR
Before 0.86 ± 0.052 0.87 ± 0.053 0.53
After 0.86 ± 0.05 0.87 ± 4.11 0.61
P‡ 0.38 0.53
BMI body mass index, WC waist circumference, HC hip circumference, WHR
waist to hip ratio, †P values for ANOCOVA after adjustment for age, gender,
duration of the disease and variable’s baseline value; ‡P values for paired
t-test. Data are presented as mean ± SD or number (percent), the bolded
P values are statistically significant
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Discussion
In the current study we showed a meaningful impact of 8
weeks treatment with Nigella sativa on thyroid function,
anthropometric features and serum VEGF concentrations
in patients with Hashimoto’s thyroiditis. However changes
in serum Nesfatin-1 concentrations were not significant.
These findings were in accordance of findings of two ani-
mal studies; in one study by Khalawi AA [25] Nigella
sativa oil improved hypothyroid status and decreased
serum TSH concentrations in rats; in other animal study
by Al-Asoom et al. [28] daily oral administration of
800 mg/kg Nigella sativa in male Wistar rats reduced
serum thyroxine concentrations. However in our study,
for the first time, we clearly demonstrated its beneficial
role on improving thyroid function in human.
The seeds of Nigella sativa known as black seeds or
black cumin have long been used in folk medicine in the
middle and Far East as a traditional medicine for a wide
Table 2 Dietary intakes of energy and nutrients in treatment
groups before and after intervention
N Nigella sativa Placebo P†
N = 20 N = 20
Total calories (kcal/d)
Before 2251.90 ± 349.58 2208.95 ± 327.80 0.69
After 2236.40 ± 248.27 2265.45 ± 270.73 0.72
P‡ 0.77 0.32
Carbohydrate (%)
Before 57.11 ± 2.90 57.07 ± 3.78 0.97
After 57.24 ± 2.71 57.58 ± 3.32 0.72
P‡ 0.26 0.67
Protein (%)
Before 15.73 ± 1.68 15.07 ± 1.29 0.17
After 15.77 ± 1.36 15.10 ± 1.81 0.19
P‡ 0.94 0.94
Fat (%)
Before 27.34 ± 2.15 26.57 ± 2.32 0.28
After 26.56 ± 1.96 26.13 ± 2.48 0.55
P‡ 0.51 0.51
Vitamin E (mg/d)
Before 2.98 ± 1.08 3.43 ± 1.48 0.36
After 2.89 ± 1.64 3.40 ± 1.19 0.28
P‡ 0.80 0.96
Vitamin C (mg/d)
Before 79.75 ± 22.69 75.67 ± 17.24 0.52
After 28.37 ± 11.84 75.45 ± 15.36 0.59
P‡ 0.77 0.91
Data are presented as mean ± SD, †P values for ANOCOVA after adjustment for
age, gender, duration of the disease and variable’s baseline value; ‡P values
for paired t-test
Table 3 Metabolic parameters in treatment groups before and
after intervention
N Nigella sativa Placebo P†
N = 20 N = 20
TSH (mIU/l)
Before 6.42 ± 3.86 8.14 ± 7.28 0.35
After 4.13 ± 2.35 8.27 ± 7.21 0.02
P‡ 0.03 0.40
T3 (mmol/l)
Before 0.92 ± 0.27 1.18 ± 0.36 0.017
After 1.06 ± 0.34 1.16 ± 0.35 0.39
P‡ 0.008 0.15
T4 (mmol/l)
Before 8.07 ± 2.56 7.97 ± 3.11 0.91
After 8.89 ± 1.43 7.63 ± 2.23 0.04
P‡ 0.21 0.32
Anti-TPO (IU/ml)
Before 294.55 ± 210.05 278.10 ± 170.77 0.78
After 147.99 ± 158.33 274.30 ± 167.20 0.01
P‡ 0.019 0.28
Nesfatin-1 (ng/ml)
Before 41.80 ± 28.33 25.86 ± 20.91 0.049
After 37.63 ± 5.91 26.75 ± 23.95
P‡ 0.34 0.69
VEGF (ng/L)
Before 3521.13 ± 395.95 2101.73 ± 339.29 0.17
After 2100.17 ± 36,082 2100.17 ± 360.82 0.25
P‡ 0.02 0.99
Data are presented as mean ± SD. † P values for ANOCOVA after adjustment
for age, gender and baseline concentration of parameter; ‡P values for paired
t-test. TSH, thyroid-stimulating hormone; T3 triiodothyronine, T4 thyroxine,
VEGF vascular endothelial growth factor, the bolded P values are statistically
significant
Table 4 Stepwise multivariate linear regression analysis in Nigella-
sativa treated group with changes in VEGF and Nesfatin-1 as
dependent variables and changes in anthropometric variables and
thyroid hormones as dependent variables
B SE β t P
Δ Nesfatin (as dependent variable)
Δ WHR 387.54 183.92 0.24 2.10 0.05
Δ TSH 1.34 0.63 0.30 2.11 0.05
ΔT3 −59.11 14.49 −0.63 −4.07 0.001
Δ VEGF (as dependent variable)
ΔWHR 35449.84 18234.88 0.31 1.94 0.05
WHR waist to hip ratio, TSH thyroid-stimulating hormone, T3 triiodothyronine,
T4 thyroxine, VEGF vascular endothelial growth factor, B unstandardized coefficient,
SE standard error, β standardized coefficient, t the student’s t distribution, P level
of significance
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range of disease including infections, obesity, hyperten-
sion and gastrointestinal problems [21]. Its most prom-
inent constituent with well- known antioxidant, anti-
inflammatory and anti-cancer properties is thyimoqui-
none [29]. Thyimoquinone has potential cytoprotective
and anti-inflammatory effects; it has been reported that
its anti-inflammatory effects are induced by up-regulated
expression of heme-oxygenase-1 and suppression of the
cyclooxygenase-2 (COX-2) expression in different cell lines
[30]. Thyimoquinone also differentially modulated thyroid
hormones and improved thyroid status in rats [31]. Thera-
peutic effects of Nigella sativa against hypothyroidism is
mostly attributed to its antioxidant effects which have been
proved in numerous studies [32–34]. It has also been sug-
gested that Nigella sativa protects the hyperplasic changes
of thyroid parenchyma in hypothyroid rats [25]. Accord-
ingly, increment in T3 concentrations after treatment with
Nigella sativa in the current study, has also been reported
in the study by Ismail et al. [35] and the authors concluded
that Nigella sativa could raise the lowered serum triiodo-
thyronine concentration without changing the concentra-
tion of serum TSH because of its potential ability in
repairing the thyroid gland and resynthesizing the thyroid
hormone; therefore its therapeutic action could be in part
due to antioxidant defense system. Accordingly, reduction
of serum anti-TPO concentrations after treatment with
Nigella sativa could be explained by its immunomodulatory
effects approved previously by its protective roles against
several autoimmune disease including type 1 diabetes melli-
tus and experimental autoimmune encephalomyelitis (EAE)
[36, 37]. The possible underlying mechanisms of immuno-
modulatory effects of Nigella sativa are reduced synthesis of
auto-antibodies, reduced innate and acquired immune cell
markers and reduction in transforming growth factor
(TGF)-β and interleukin (IL)-23 concentrations [36–38].
VEGF is minimally expressed in normal human thy-
roid cells [39]; however in pathological situations, en-
hanced TSH concentrations, is a potent stimulator of
VEGF secretion [11]. It has been shown that VEGF and
one of its receptors, Flt-1, are present in epithelial cells
of the thyroid, and VEGF contributes to the regulation
of development and function of thyroid epithelial cells
[10]. Higher VEGF concentrations are associated with
increased risk of recurrence and decreased disease-free
survival in papillary thyroid cancer [40]. Strong expres-
sion of VEGF has been reported in thyroiditis and thy-
roid carcinomas [41]; therefore it is a critical cytokine in
tumor angiogenesis and will be a potent target of diag-
nosis and therapy. In the current study, Nigella sativa
had a strong impact in reducing VEGF concentrations in
Hashimoto’s thyroiditis. It is mostly because of anti-
angiogenic effects of Nigella sativa and its major bio-
active compound, thyimoquinone, which has been
proven previously in different cancer cell lines [42, 43].
Moreover, in the current study, change in WHR was a
significant positive predictor of changes in serum VEGF
in Nigella sativa treated group. In fact, VEGF is a multi-
functional cytokine and its elevated concentration has
been reported previously in several metabolic disorders
including type 2 diabetes mellitus and polycystic ovary
syndrome. A positive association between serum VEGF
and its different genomic variants with the components
of metabolic syndrome including central obesity and
waist to hip ratio has also been previously reported
[44, 45]. This relationship arise from this fact that adipo-
cytes, specially white adipose tissue cells, produce VEGF
which may act as an angiogenic and vascular survival fac-
tor for the omental vasculature and has paracrine or sys-
temic endocrine actions, these might hypothetically
impact on adipose expansion or the vascular comorbidi-
ties of obesity related disease [46]. In this context, it is in-
teresting that Randeva et al. could reported a strong
correlation of serum VEGF with waist-to-hip ratio in a
considerable cohort of individuals (χ2 = 17.42; P < 0.001)
[47], a measure that, is suggested to be a better marker
of subclinical arteriosclerosis and endothelial dysfunc-
tion [48] which are common clinical consequences of
Hashimoto’s thyroiditis [49, 50].
Weight reducing effects of Nigella sativa has been ob-
served in previous studies; Zaoui A [51] reported a signifi-
cant reduction in body weight in rats after 6 weeks
treatment with Nigella sativa fixed oil (P < 0.001). In other
study 3 month supplementation with 1.5 g per day of
powdered Nigella sativa in central obese men significantly
reduced body weight [52]. One suggested mechanism is
increasing mean rates of satiety and fullness [53]; although,
we did not observe any change in dietary energy or nutri-
ent intakes after intervention. Other possible mechanisms
are reduced lipid absorption, increased energy expenditure,
decreased pre-adipocyte differentiation and proliferation,
or decreased lipogenesis and increased lipolysis [54]. The
suggested underlying mechanisms of the effects Nigella
sativa and its major ingredient thymoquinone’s on thyroid
health and body weight are summarized in Fig. 2.
Hashimoto’s thyroiditis is more prevalent among fe-
males compared with males and women are up to 10
times more likely to develop the disease compared with
men [55]. This strong female association remains unex-
plained although our hunch is that sex steroids have
the critical role, as there is compelling evidence for
such effects in animal models of many types of auto-
immunity [56]. Other possible explanations include
skewed X chromosome inactivation and fetal microchi-
merism [57]. Accordingly, the number of the female
participants in the current study was more than men,
but the gender distribution among two groups were
equal. Therefore, the possible confounding effect of
gender could be rule out. Moreover, the comparisons
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between all of the study parameters are adjusted for the
possible confounding effects of age, gender and vari-
able’s baseline values by ANCOVA.
In the current study serum Nesfatin-1 did not change
after Nigella sativa supplementation in Hashimoto’s thy-
roiditis patients. The studies regarding the relationship
between serum Nesfatin-1 concentrations and thyroid
dysfunction are scarce and conflicting. One study in
children demonstrated its reduced concentrations in
children with untreated subclinical hypothyroidism [13];
while, other study by Sahin et al. [58] reported no differ-
ence in serum Nesfatin-1 concentrations in patients with
hypothyroidism compared with healthy control group.
Nesfatin-1 is colocalized with TRH and affects the mem-
brane potential of TRH neurons in the paraventricular
nucleus, which is known to be closely related to the
regulation of thyroid function [15]. However we did not
find any change in its concentrations after treatment
with Nigella sativa. It could be due to relatively small
sample size or treatment duration.
Conclusions
We have demonstrated beneficial effects of Nigella sativa
in improving thyroid status, reducing VEGF and body
weight in patients with Hashimoto’s thyroiditis. Although
no significant change in serum Nesfatin-1 concentrations
has been observed, change in anthropometric variables
and thyroid hormones were significant predictors of
changes in serum Nesfatin-1 concentrations.
Abbreviations
BMI: Body mass index; HC: Hip circumference; T3: Triiodotyronine;
T4: Thyroxine; TG-Ab: Thyroglobulin antibody; TPO-Ab: Thyroid peroxidase
antibody; TRH: Thyrotropin releasing hormone; TSH: Thyroid stimulating
hormone; VEGF: Vascular endothelial growth factor; WC: Waist circumference;
WHR: Waist to hip ratio
Acknowledgement
The current research was financially supported by a grant from Tabriz University
of Medical Sciences.
Funding
This research has been performed by a grant from Tabriz University of Medical
Sciences (Project number: 93173).
Availability of data and materials
The data are available for any scientific use with kind permission.
Authors’ contributions
MAF conceived and designed the project and wrote the manuscript and
performed the statistical analysis, PD was involved in manuscript revision, ST
performed the sampling and data collection and MMA was involved in lab
works. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
All participants signed a written informed consent approved by the Institutional
Review Board of Tabriz University of Medical Sciences. The study design and
protocol was approved by the ethical committee of Tabriz University of Medical
Sciences (Project number: 93173). The study has also been registered in Iranian
registry of clinical trials (registration number IRCT2015021719082N4- Registered
March-15-2015).
Fig. 2 The probable mechanisms of the effects of Nigella Sativa and its major ingredient Thymoquione on thyroid status and body weight. TSH
thyroid stimulating hormone, T3 triiodotyronin, VEGF vascular endotheilial growth factor
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